PRQR - ProQR Therapeutics N.V.
| Previous Close | 11.68 |
| Open | 11.78 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 11.38 - 11.90 |
| 52 Week Range | 3.50 - 24.00 |
| Volume | 174,025 |
| Avg. Volume | 236,346 |
| Market Cap | 445.872M |
| Beta (3Y Monthly) | 0.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.31 |
| Earnings Date | May 7, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.50 |
- GlobeNewswire•3 days ago
ProQR to Present at Three Scientific Conferences in April
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.
- GlobeNewswire•7 days ago
ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
- GlobeNewswire•7 days ago
ProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.
- Zacks•8 days ago
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
- GlobeNewswire•10 days ago
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 2/3 ILLUMINATE clinical trial for sepofarsen (formerly named QR-110) in patients with Leber’s Congenital Amaurosis 10 (LCA10). “Inherited retinal degenerations caused by mutations in the CEP290 gene frequently lead to blindness in early childhood. No form of therapy is currently available,” said Dr. Katarina Stingl of the Center for Ophthalmology in Tübingen, Investigator in the ILLUMINATE trial.
- GlobeNewswire•24 days ago
ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.
- GlobeNewswire•last month
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out of the Dystrophic Epidermolysis Bullosa (DEB) activities into the newly formed company, Wings Therapeutics. Wings Therapeutics is formed and financed by EB Research Partnership (EBRP), the largest global non-profit dedicated to treating and curing EB. Wings Therapeutics will be led by interim CEO Mark de Souza, PhD, former CEO of Lotus Tissue Repair and Hal Landy, MD, former medical advisor to Lotus Tissue Repair and CMO of Enobia.
- GlobeNewswire•last month
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). "There are no effective treatments for most inherited retinal diseases, including Usher syndrome, and blindness often results,” said David G. Birch, Ph.D., Principal Investigator of STELLAR and Scientific Director of the Retina Foundation of the Southwest in Dallas, Texas. “The STELLAR study is one of the first studies of its kind exploring the impact of ProQR’s RNA therapies on patients with Usher syndrome due to an Exon 13 mutation.
- GlobeNewswire•2 months ago
ProQR to Present at Cowen Health Care Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 05, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.
- Zacks•2 months ago
Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.
- GlobeNewswire•2 months ago
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
- Zacks•2 months ago
Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.
- Zacks•3 months ago
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
- GlobeNewswire•3 months ago
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and commercialization of RNA medicines for inherited retinal diseases (IRDs). The management team will elaborate on this strategy and present advancements across its broader clinical development pipeline during an R&D day event being held today in New York. ProQR plans to independently advance its pipeline of RNA medicines to establish a multi-product, platform company in IRD.
- Simply Wall St.•3 months ago
Should You Worry About ProQR Therapeutics N.V.’s (NASDAQ:PRQR) CEO Salary Level?
Daniel de Boer became the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) in 2012. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- GlobeNewswire•4 months ago
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase 2/3 pivotal trial (“ILLUMINATE”) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. LCA is the leading genetic cause of childhood blindness. Based on data from the ongoing sepofarsen Phase 1/2 trial (PQ-110-001), the doses for the Phase 2/3 trial will be 40 μg (with an 80 μg loading dose) and 80 μg (with a 160 μg loading dose).
- Zacks•4 months ago
Company News For Jan 3, 2019
Companies in the news are: GOOGL, TSLA, PRQR, OHI and MRT
- GlobeNewswire•4 months ago
ProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January.
- Zacks•4 months ago
Best Sector of 2018 and its Hit ETFs & Stocks
Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.
- GlobeNewswire•4 months ago
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. Fast Track designation is granted by FDA to drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need.
- GlobeNewswire•4 months ago
ProQR Therapeutics Added to NASDAQ Biotechnology Index
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 24, 2018 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative.
- Insider Monkey•4 months ago
Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds?
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost a third of its value since the end of July. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 30 S&P 500 stocks […]
- GlobeNewswire•4 months ago
ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Nature Medicine. “It was enormously gratifying to see robust improvements in visual acuity and significant augmentations in the patient’s ability to detect lights, and impressive to observe these effects within the first three months following a single injection,” said Professor Artur V. Cideciyan, Ph.D., who was one of the co-investigators at the Scheie Eye Institute of the University of Pennsylvania.
- GlobeNewswire•4 months ago
ProQR Announces Strategic Changes to the Management Team and Key New Hires
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation.
- GlobeNewswire•4 months ago
ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it was awarded an innovation credit by the Dutch government for the clinical development and efforts to obtain marketing approval (NDA/MAA) for the QR-110 program that is being developed for patients with Leber’s congenital amaurosis 10 (LCA10), a genetic eye disease that is the leading cause of childhood blindness. Repayment of the credit is triggered only by market approval of QR-110. The Innovation Credit is awarded by the Dutch government through its agency RVO of the Ministry of Economic Affairs, and is aimed at the development of promising innovations.
